接种COVID-19疫苗女性中死产和早产的减少:一项关于疫苗接种率与围产结局的多中心队列研究
该回顾性多中心队列研究分析了澳大利亚墨尔本12家公立妇产医院2021年7月1日至2022年3月31日分娩的32536名女性,比较接种与未接种COVID-19疫苗者的围产结局。接种组死产率0.2% vs 未接种组0.8%(调整OR 0.18,95%CI 0.09-0.37,P<.001),总早产<37周5.1% vs 9.2%(调整OR 0.60,95%CI 0.51-0.71,P<.001)。接种与死产和早产减少相关,未增加胎儿生长或发育不良影响。
要点
- 接种组死产率0.2% vs 未接种组0.8%(调整OR 0.18,95%CI 0.09-0.37,P<.001)。
- 接种组总早产<37周5.1% vs 未接种组9.2%(调整OR 0.60,95%CI 0.51-0.71,P<.001)。
- 接种组重大先天畸形率2.4% vs 未接种组3.0%(调整OR 0.72,95%CI 0.56-0.94,P=.02)。
核心结论
- 孕期接种COVID-19疫苗与死产和早产减少相关,且未对胎儿生长或发育产生不良影响。
- 疫苗覆盖率受已知健康社会决定因素的显著影响。
研究设计与样本
- 回顾性多中心队列研究,纳入澳大利亚墨尔本全部12家公立妇产医院2021年7月1日至2022年3月31日期间≥20周妊娠的分娩数据。
- 共分析32536名女性的分娩,其中接种疫苗17365名(53.4%),未接种15171名(47.6%)。
- 围产结局比较限于妊娠20至43周完全落在9个月数据收集期内的接种与未接种女性。
- 主要结局为至少24周妊娠单胎(排除先天畸形)的死产率和早产率(自发性和医源性)。
- 采用逆倾向评分加权回归调整多个协变量计算调整OR,P<.05为统计学显著。
主要发现
- 接种组死产率0.2% vs 未接种组0.8%(调整OR 0.18,95%CI 0.09-0.37,P<.001)。
- 接种组总早产<37周5.1% vs 未接种组9.2%(调整OR 0.60,95%CI 0.51-0.71,P<.001)。
- 接种组自发性早产2.4% vs 未接种组4.0%(调整OR 0.73,95%CI 0.56-0.96,P=.02)。
- 接种组医源性早产2.7% vs 未接种组5.2%(调整OR 0.52,95%CI 0.41-0.65,P<.001)。
- 接种组重大先天畸形率2.4% vs 未接种组3.0%(调整OR 0.72,95%CI 0.56-0.94,P=.02),限制于20周前接种者该结果仍显著。
关键数值与推荐
- 接种组死产率0.2% vs 未接种组0.8%(调整OR 0.18,95%CI 0.09-0.37,P<.001)。
- 接种组总早产<37周5.1% vs 未接种组9.2%(调整OR 0.60,95%CI 0.51-0.71,P<.001)。
- 接种组自发性早产2.4% vs 未接种组4.0%(调整OR 0.73,95%CI 0.56-0.96,P=.02)。
- 接种组医源性早产2.7% vs 未接种组5.2%(调整OR 0.52,95%CI 0.41-0.65,P<.001)。
- 接种组重大先天畸形率2.4% vs 未接种组3.0%(调整OR 0.72,95%CI 0.56-0.94,P=.02)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: COVID-19 infection in pregnancy is associated with a higher risk of progression to severe disease, but vaccine uptake by pregnant women is hindered by persistent safety concerns. COVID-19 vaccination in pregnancy has been shown to reduce stillbirth, but its relationship with preterm birth is uncertain. OBJECTIVE: This study aimed to measure the rate of COVID-19 vaccine uptake among women giving birth in Melbourne, Australia, and to compare perinatal outcomes by vaccination status. STUDY DESIGN: This was a retrospective multicenter cohort study conducted after the June 2021 government recommendations for messenger RNA COVID-19 vaccination during pregnancy. Routinely collected data from all 12 public maternity hospitals in Melbourne were extracted on births at ≥20 weeks' gestation from July 1, 2021 to March 31, 2022. Maternal sociodemographic characteristics were analyzed from the total birth cohort. Perinatal outcomes were compared between vaccinated and unvaccinated women for whom weeks 20 to 43 of gestation fell entirely within the 9-month data collection period. The primary outcomes were the rates of stillbirth and preterm birth (spontaneous and iatrogenic) in singleton pregnancies of at least 24 weeks' gestation, after exclusion of congenital anomalies. Secondary perinatal outcomes included the rate of congenital anomalies among infants born at ≥20 weeks' gestation and birthweight ≤third centile and newborn intensive care unit admissions among infants born without congenital anomalies at ≥24 weeks' gestation. We calculated the adjusted odds ratio of perinatal outcomes among vaccinated vs unvaccinated women using inverse propensity score-weighting regression adjustment with multiple covariates; P<.05 was considered statistically significant. RESULTS: Births from 32,536 women were analyzed: 17,365 (53.4%) were vaccinated and 15,171 (47.6%) were unvaccinated. Vaccinated women were more likely to be older, nulliparous, nonsmoking, not requiring an interpreter, of higher socioeconomic status, and vaccinated against pertussis and influenza. Vaccination status also varied by region of birth. Vaccinated women had a significantly lower rate of stillbirth compared with unvaccinated women (0.2% vs 0.8%; adjusted odds ratio, 0.18; 95% confidence interval, 0.09-0.37; P<.001). Vaccination was associated with a significant reduction in total preterm births at <37 weeks (5.1% vs 9.2%; adjusted odds ratio, 0.60; 95% confidence interval, 0.51-0.71; P<.001), spontaneous preterm birth (2.4% vs 4.0%; adjusted odds ratio, 0.73; 95% confidence interval, 0.56-0.96; P=.02), and iatrogenic preterm birth (2.7% vs 5.2%; adjusted odds ratio, 0.52; 95% confidence interval, 0.41-0.65; P<.001). Infants born to vaccinated mothers also had lower rates of admission to the neonatal intensive care unit. There was no significant increase in the rate of congenital anomalies or birthweight ≤3rd centile in vaccinated women. Vaccinated women were significantly less likely to have an infant with a major congenital anomaly compared with the unvaccinated group (2.4% vs 3.0%; adjusted odds ratio, 0.72; 95% confidence interval, 0.56-0.94; P=.02). This finding remained significant even when the analysis was restricted to women vaccinated before 20 weeks' gestation. CONCLUSION: COVID-19 vaccination during pregnancy was associated with a reduction in stillbirth and preterm birth, and not associated with any adverse impact on fetal growth or development. Vaccine coverage was substantially influenced by known social determinants of health.
引用
- Hui L, Marzan MB, Rolnik DL, et al. Reductions in stillbirths and preterm birth in COVID-19-vaccinated women: a multicenter cohort study of vaccination uptake and perinatal outcomes. Am J Obstet Gynecol. 2022. PMID: 36336084. doi:10.1016/j.ajog.2022.10.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。